Who Supplies Cabozantinib to India from BELGIUM

To import finished pharmaceutical formulations containing Cabozantinib into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the foreign manufacturer and the Indian importer obtain necessary registrations and licenses. The foreign manufacturer must secure a Certificate of Pharmaceutical Product (CoPP) from the CDSCO, ensuring compliance with Indian standards. The Indian importer is required to obtain an Import License from the Directorate General of Foreign Trade (DGFT) and register the product with the CDSCO. The registration process involves submitting Form 40/41, along with supporting documents such as the CoPP, manufacturing license, and stability data. The timeline for import drug registration can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the CDSCO's processing time. For Cabozantinib formulations under HS Code 30049099, specific requirements include providing detailed product information, manufacturing details, and evidence of compliance with Good Manufacturing Practices (GMP).

Imported finished pharmaceutical formulations containing Cabozantinib must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV conditions, must be provided to demonstrate the product's shelf-life and efficacy. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the shipments. If a batch fails to meet the required standards, it may be rejected, leading to potential delays or the need for re-exportation.

Between 2024 and 2026, the CDSCO introduced stricter regulations for the importation of pharmaceutical products, including mandatory import registration and licensing to prevent the sale of unapproved or illegal medicines in the Indian market. These measures aim to streamline the import process and ensure that all imported drugs meet the required quality, safety, and efficacy standards. The introduction of the Production Linked Incentive (PLI) scheme has also impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. While the PLI scheme primarily targets domestic production, it indirectly affects import policies by promoting self-reliance in pharmaceutical manufacturing.

India imports finished Cabozantinib formulations primarily due to the unavailability of certain patented or branded formulations domestically. Specific dosage forms or strengths may not be manufactured locally, necessitating imports to meet patient needs. The market size for Cabozantinib in India is significant, with a growing number of patients requiring treatment for advanced renal cell carcinoma and other indications. The import dependency arises from the need to access these specialized formulations that are not produced within the country.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the imported value. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is levied. This results in a total landed duty of approximately 23.536% of the CIF (Cost, Insurance, and Freight) value. There are no specific exemptions or concessional rates for imports from Belgium under this HS code.

Belgium's pharmaceutical industry is renowned for its high-quality standards and advanced manufacturing capabilities. For Cabozantinib formulations, Belgium offers specialized dosage forms and formulations that may not be available from other suppliers. While other countries like China, Germany, and the United States also export pharmaceutical products to India, Belgium's competitive advantage lies in its adherence to stringent quality controls and compliance with international regulatory standards. This ensures that Belgian products meet the expectations of Indian regulators and healthcare providers.

India imports finished Cabozantinib formulations from Belgium due to the unavailability of certain patented or branded formulations domestically. Specific dosage forms or strengths may not be manufactured locally, necessitating imports to meet patient needs. Belgium's pharmaceutical industry offers high-quality products that comply with international regulatory standards, ensuring safety and efficacy. Additionally, Belgium's adherence to stringent quality controls and compliance with international regulatory standards ensures that their products meet the expectations of Indian regulators and healthcare providers.

When compared to other potential suppliers like China, Germany, and the United States, Belgium offers a competitive advantage in terms of product quality and regulatory compliance. While China may offer lower prices, concerns about quality and regulatory adherence can be a drawback. Germany and the United States also provide high-quality products but may have higher costs associated with their goods. Belgium's balance of quality, compliance, and cost-effectiveness makes it an attractive source for finished pharmaceutical formulations containing Cabozantinib.